Complete list
LDL cholesterol, triglycerides and cholesterol as risk factor for CVD
Ference, M., Kastelein, J., Ray, K et al (2019) Association of triglyceride lowering LPL variants and LDL-C lowering LDLR variants with risk of coronary heart disease. JAMA. 321. 4. 364-373. Available at: Jamanetworkfullarticle
Ference, M., Ginsburg, H., Graham, I., Ray, K et al (2017) Low density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic and clinical studies. A consensus statement from the European Atherosclerosis Society Pane. European Heart Journal. Available at: https://academic.oup.com/eurheartj/article-lookup/doi/10.1093/eurheartj/ehx144
Yusuf, S., Hawken, S., Ôunpuu, S., Dans, T et al (2004) Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case control study. The Lancet. Available at: http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(04)17018-9/fulltext
Familial Chylomicronaemia Syndrome
Stroes, E., Moulin, P., Parhofer, K et al (2017) Diagnostic algorithm for familial chylomicronemia syndrome. Atherosclerosis. Supplement. 23. 1-7. Full supplement available
Familial Hypercholesterolaemia
PCCJ sponsored Familial Hypercholesterolaemia Series
For free access to these articles, you can sign up to the PCCJ Plus Website at www.pccj.eu
Milne D (2013) Its not just a high cholesterol, it can be an indicator of a genetic disorder. Prim Care Cardiovasc Journal. 6. pp122-124.
Neely, R (2013). The importance of early diagnosis: how to identify patients with FH for diagnosis and referral. Prim Care Cardiovasc Journal. 7. 1. pp31-35
Thompson, G. and Seed, M (2014) The management of familial hypercholesterolaemia. Prim Care Cardiovasc Journal. 7 pp89-91
Humphries, S. and Futema, M. (2015) What's new in FH genetics? Prim Care Cardiovasc Journal. 1. 1. Epublication online
Green, P., Qureshi, N (2017) The role of primary care in patients with FH. PCCJ. Online publication.
Wald, D., Bestwick, M. et al (2016) Child parent familial hypercholesterolaemia screening in primary care. New England Journal of Medicine. 375. pp1628-1637
France, M., Rees, A., Datta, D et al (2016) HEART UK statement on the management of homozygous familial hypercholesterolaemia in the United Kingdom. Atherosclerosis. Available at: http://www.atherosclerosis-journal.com/article/S0021-9150(16)31420-4/fulltext
Paediatrics and Young People
Priestley-Barnham, L. et al (2019) Diagnosis and management of children and young people with Familial Hypercholesterolaemia. British Journal of Cardiac Nursing. 14. 1. pp22-30.
Vuorio, A., Kuoppala, J., Kovanen, P.T., Humphries, S., Tonstad, S., Weigman, A et al (2014). Statins for children with Familial Hypercholesterolaemia. Cochrane Database of Systematic Review. 7. Full review available
Lipoprotein (a)
Burgess, S., Ference, B et al (2018) Association of LPA variants with risk of coronary disease and the implications for Lipoprotein (a) lowering therapies: A mendelian randomization analysis. JAMA Cardiology. 3. 7. pp 619-672. Full review available
O'Donoghue, M. et al (2019) Lipoprotein (a), PCSK9 inhibition and Cardiovascular Risk: Insights from the FOURIER Trial. Circulation. Vol 139, No 12. pp1483-1492. Abstract available here
Pare, G et al (2019) Lipoprotein (a) Levels and the Risk of Myocardial Infarction among 7 Ethnic Groups. Circulation. Vol 138. No 12. pp1472-1482. Abstract available here
Thanassoulis, G. (2019) Editorial. Screening for High Lipoprotein (a). The Time is Now. Circulation. Vol 139. pp1493-1496. Full editorial available here
Statins and Treatments:
The CTT Collaborists (2019) Efficacy and safety of statin therapy in older people: a meta analysis of individual participant data from 28 randomised controlled trials. The Lancet. Vol 393, issue 10170. pp 407-415. Available at: Download full paper
Mach, F.m Ray, K. et al (2018) Adverse effects of statin therapy: perception vs the evidence – focus on glucose homeostasis, cognitive, renal and hepatic function, haemorrhagic stroke and cataract. European Heart Journal 0. 1-18. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6047411/
Newman, C., Preiss, D et al (2018) Statin Safety and Associated Adverse Events: A Scientific Statement From the American Heart Association. (Arterioscler Thromb Vasc Biol. 2018;38:e00-e00 Available at: https://www.ahajournals.org/doi/pdf/10.1161/ATV.0000000000000073
Baigent, C., Landray, M, Reith, C et al (2011) The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. The Lancet. 377. 9784. Pp2181-2192. Available online: http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(11)60739-3/fulltext
Cholesterol Treatment Trialists (CTT) Collaborators. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 2010. vol 376, no 9753. 1670-1680
Cholesterol Treatment Trialists (CTT) Collaborators. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease. Meta analysis of individual data from 27 randomised trials. Lancet 2012. Aug 11, 380 (9841) 581-590:
Cannon, C., Blazing, M., Giugliano, R et al (2015) Ezetimibe added to statin therapy after acute coronary syndromes. New England Journal of Medicine. 372. pp2387-2397. Available at: http://www.nejm.org/doi/full/10.1056/NEJMoa1410489#t=articleTop
Collins, R., Reith, C et al (2016) Interpretation of the evidence for the efficacy and safety of statin therapy. Lancet. 388, 10059. pp2532-2561. Available at: http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(16)31357-5/abstract
Finegold JA, Manisty CH, Goldacre B, Barron AJ, Francis DP. What proportion of symptomatic side effects in patients taking statins are genuinely caused by the drug? Systematic review of randomised placebo controlled trials to aid individual patient choice. European Journal of Preventative Cardiology. 2014, 21: 464 (abstract only)
Ridker, P., Danielson, E., et al (2008) JUPITER STUDY: Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. New England Journal of Medicine. 359. Pp2195-2207. Available at: http://www.nejm.org/doi/full/10.1056/NEJMoa0807646#t=article
Thompson G (2008) The Cholesterol Controversy. Royal Society of Medicine Press Ltd, London
Diet
Sacks. F. , Lichenstein, A et al (2017) Dietary fats and cardiovascular disease, a presidential advisory from the American Heart Association. Circulation. 136. ppe1-e23. Available at Circulation online
Estruch, R., Ros, E et al (2013) Primary prevention of cardiovascular disease with a Mediterranean diet. (PREDIMED) The New England Journal of Medicine. 368. 14. Pp. 1279-90
Mensink RP (2016) Effects of saturated fatty acids on serum lipids and lipoproteins: a systematic review and regression analysis. World Health Organisation
European Food safety Authority (EFSA) 2010 Scientific Opinion on Dietary Reference Values for Fats. EFSA Journal 2010; 8(3):1461 [107 pp.].
Scientific Advisory Committee on Nutrition (2015) Carbohydrates and Health. Available online: https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/445503/SACN_Carbohydrates_and_Health.pdf
Lipoprotein Apheresis:
Pottle A., Thompson, G., Barbir, B., Bayly, G., Cegla, J., Cramb, R., Dawson, T et al (2019) Lipoprotein apheresis efficacy, challenges and outcomes: a descriptive analysis from the UK Lipoprotein Apheresis Registry. 1989-2017. Atherosclerosis: 290. 44-51
Thompson GR, HEART UK LDL Apheresis Working Group. Recommendations for the use of LDL apheresis (2008) Atherosclerosis: 198; 247-255. (Abstract only)
Thompson GR, Barbir M, Davies D et al. Efficiency criteria and cholesterol targets for LDL apheresis. (2010) Atherosclerosis: 208; (Abstract only)
CVD risk
Joint British Societies for the Prevention of Cardiovascular Disease (2014) Joint British Societies’ consensus recommendations for the prevention of cardiovascular disease (JBS3) Heart 100. pp. 1-67. Available at: www.jbs3risk.com
National Institute for Health and Care Excellence (2014) Cardiovascular disease: risk assessment and reduction, including lipid modification. Available at: https://www.nice.org.uk/guidance/cg181
Scottish Intercollegiate Guidelines Network (SIGN) Risk estimation and the prevention of cardiovascular disease.
Public Health England (2014) Adult obesity and type 2 diabetes. Available online : https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/338934/Adult_obesity_and_type_2_diabetes_.pdf